Thursday, January 22, 2015 10:29:13 AM
http://www.meipharma.com/our-programs/clinical-trials-0
MEIP
Recent MEIP News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 09:20:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:05:07 PM
- MEI Pharma Reports Fiscal Year End 2024 Cash Position • Business Wire • 09/19/2024 08:01:00 PM
- MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives • Business Wire • 08/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:25:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:06:33 PM
- MEI Pharma to Consider Strategic Alternatives • Business Wire • 07/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 05:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:02:15 PM
- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 05/09/2024 08:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:00:47 PM
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM